Background about Glioblastoma and the new drug
It is approved in India, China, and other countries for Head and Neck cancer.
About the Study
The patients were divided into 2 groups:
Patients in both groups underwent tumor resection surgery.
Time until disease progression (also called Progression-Free Survival, PFS), Survival and side effects were assessed.
The median time until disease progression was 12.4 months and 8.2 months in the 2 groups, respectively
The median Survival was 27.3 months and 16.7 months, respectively
In patients with unmethylated MGMT, the median time until disease progression and Survival were significantly better in patients treated with Nimotuzumab:
The median time until disease progression was 19.3 vs 6.7 months
The median Survival was 20.2 vs 13.8 months
During the treatment period, no significant difference in toxicity was noted between the 2 groups.
Conclusion for Newly Diagnosed Glioblastoma Patients
Nimotuzumab demonstrated good safety and tolerability.
Talk to us so see if we can help you to actually get the most advanced treatments
Because we, do not give up on life!
Contact us 24/7 –
Call center +44.2082.426.039